Evaluation of a New (177)Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5

Targeted radionuclide therapy of somatostatin receptor (SST)-expressing tumors is only partially addressed by the established somatostatin analogs having an affinity for the SST subtype 2 (SST2). Aiming to target a broader spectrum of tumors, we evaluated the bis-iodo-substituted somatostatin analog...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansi, Rosalba, Nicolas, Guillaume Pierre, Del Pozzo, Luigi, Abid, Karim Alexandre, Grouzmann, Eric, Fani, Melpomeni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570871/
https://www.ncbi.nlm.nih.gov/pubmed/32932783
http://dx.doi.org/10.3390/molecules25184155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570871/
https://www.ncbi.nlm.nih.gov/pubmed/32932783
http://dx.doi.org/10.3390/molecules25184155

Ejemplares similares